Geode Capital Management
CMMB

Geode Capital Management’s Chemomab Therapeutics CMMB Stock Holding History

Geode Capital Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,934
Closed -$10.8K – 4546
2024
Q2 		$10.8K Hold
2,934
– – ﹤0.01% 4540
2024
Q1 		$9.14K Hold
2,934
– – ﹤0.01% 4558
2023
Q4 		$5.99K Hold
2,934
– – ﹤0.01% 4626
2023
Q3 		$10.5K Hold
2,934
– – ﹤0.01% 4723
2023
Q2 		$15.4K Hold
2,934
– – ﹤0.01% 4686
2023
Q1 		$18.7K Hold
2,934
– – ﹤0.01% 4710
2022
Q4 		$37K Hold
2,934
– – ﹤0.01% 4673
2022
Q3 		$29K Hold
2,934
– – ﹤0.01% 4851
2022
Q2 		$43K Hold
2,934
– – ﹤0.01% 4807
2022
Q1 		$56K Hold
2,934
– – ﹤0.01% 4786
2021
Q4 		$80K Sell
2,934
-501
-15% -$17.8K ﹤0.01% 4780
2021
Q3 		$152K Buy
+3,435
New +$209K ﹤0.01% 4547

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Geode Capital Management's CMMB Position: Q3 2024 in Review

Geode Capital Management sold out of Chemomab Therapeutics (CMMB) in Q3 2024, closing a stake of 2,934 shares — an estimated $10.8K sold.

Geode Capital Management first reported a position in CMMB in Q3 2021 and held it in 12 quarters. The position peaked at $152K in Q3 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2024.

  • Geode Capital Management reported no remaining Chemomab Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 2,934 Chemomab Therapeutics shares in Q3 2024, an estimated $10.8K.
  • Geode Capital Management first reported a position in Chemomab Therapeutics in Q3 2021 and held it in 12 quarters.
  • Geode Capital Management's Chemomab Therapeutics position peaked at $152K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.